TFAP2E-DKK4 and chemoresistance in colorectal cancer

• Verfasst von: Ebert, Matthias [VerfasserIn]
• Verfasst von: Tänzer, Marc [VerfasserIn]
• Titel: TFAP2E-DKK4 and chemoresistance in colorectal cancer
• Verf.angabe: Matthias P.A. Ebert, M.D., Marc Tänzer, M.A.
• E-Jahr: 2012
• Jahr: March 8, 2012
• Umfang: 1 S.
• Fussnoten: Gesehen am 16.04.2019
• Titel Quelle: Enthalten in: The New England journal of medicine
• Ort Quelle: Waltham, Mass. : MMS, 1928
• Jahr Quelle: 2012
• Band/Heft Quelle: 366(2012), 10, Seite 966-966
• ISSN Quelle: 1533-4406
• DOI: doi:10.1056/NEJMc1201170
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1663335249

Abstract

To the Editor: Ebert et al. (Jan. 5 issue)1 report that hypermethylation of the gene encoding transcription factor AP-2 epsilon (TFAP2E) reduces its expression and is associated with chemoresistance in patients with colorectal cancer and in colorectal-cancer cell lines in vitro. The test has dramatic clinical value: the response rate increased from less than 15% among hypomethylated tumors to more than 80% among hypermethylated tumors. Methylation of this gene had a huge biologic and clinical effect. However, we have several questions. First, the methylation status differs between primary tumors and metastases in approximately 30% of tumors: were these tumors considered . . .